Pre-made Cabiralizumab benchmark antibody ( Whole mAb, anti-CSF1R therapeutic antibody, Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-087
Pre-Made Cabiralizumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cabiralizumab is developed as a monoclonal antibody antagonist targeted CSF1R, with potential antineoplastic activity. Upon administration, the drug inhibits the binding of CSF1R to CSF1 and interleukin-34 (IL-34) via binding to CSF1R expressed on monocytes, macrophages, and osteoclasts competitively.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cabiralizumab biosimilar, Whole mAb, Anti-CSF1R Antibody: Anti-FMS/CSFR/FIM2/HDLS/C-FMS/CD115/HDLS1/CSF-1R/BANDDOS/M-CSF-R therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University|
|Conditions Active||Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours|
|Conditions Discontinued||Rheumatoid arthritis|